Company Overview of Allakos Inc.
Allakos Inc., a biotechnology company, develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos Inc. was founded in 2012 and is based in San Carlos, California.
75 Shoreway Road
San Carlos, CA 94070
Founded in 2012
Key Executives for Allakos Inc.
Founder, Chief Executive Officer, President and Director
Co-Founder and Vice President of Research
Compensation as of Fiscal Year 2016.
Allakos Inc. Key Developments
Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis
Sep 15 16
Allakos Inc. announced it has initiated dosing of AK002 in a Phase 1 clinical trial in patients with systemic mastocytosis. The open-label, single ascending-dose study, being conducted in Germany, will evaluate the safety, tolerability and pharmacokinetics of AK002 and will also offer the opportunity to assess markers of activity. AK002 is a therapeutic antibody intended for the treatment of severe diseases characterized by excess activity of mast cells and eosinophils. Allakos is also conducting a Phase I healthy volunteer study with AK002 to further test the safety, pharmacokinetics and pharmacodynamics of this antibody. The study is anticipated to enroll up to 48 subjects.
Allakos Inc. Initiates Phase 2 Trial of AK001 in Patients with Nasal Polyposis
Sep 8 16
Allakos Inc. announced it has initiated a Phase 2 clinical trial of AK001, its lead therapeutic antibody, in patients with nasal polyposis with and without asthma. This multicenter trial with sites in the U.S. and Europe will evaluate the activity of two dose levels of AK001 compared with placebo. Study results are anticipated in the second half of 2017. AK001 is a therapeutic antibody currently in development for the treatment of severe inflammatory and allergic diseases characterized by excess activity of mast cells and eosinophils. AK001: AK001 is a therapeutic antibody that selectively targets mast cells and eosinophils. Binding of AK001 to specific receptors present on mast cells and eosinophils results in the inhibition of mast-cell inflammatory signaling and the removal of tissue-based eosinophils. The direct effect of AK001 on mast cells and eosinophils bypasses the redundancy of cytokine signaling pathways without directly affecting other cells of the immune system. AK001 has the potential to be of benefit in a wide spectrum of severe inflammatory and allergic diseases. Allakos has demonstrated activity of AK001 in multiple pre-clinical models and completed a Phase I clinical trial with AK001 in healthy volunteers in which it was well tolerated and demonstrated pharmacodynamic activity.
Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001
Jan 19 16
Allakos Inc. announced that it has successfully completed dosing in the Phase 1 clinical trial of AK001 in healthy volunteers and subjects with atopic disease. AK001 is a therapeutic antibody intended for the treatment of severe allergic diseases and diseases characterized by excess activity of mast cells and eosinophils. The randomized, double-blind, placebo-controlled, single-ascending-dose study enrolled 34 subjects to evaluate the safety, tolerability and pharmacokinetics of AK001 in a range of potentially active doses and to obtain early signals of pharmacodynamic activity.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries